Symposium 20: Pharmacological treatment of the patient with Non-Alcoholic Fatty Disease (NAFLD)

Authors

  • Karina Fuentes Private Hospital of Córdoba, Córdoba, Argentina

DOI:

https://doi.org/10.47196/diab.v56i3Sup.606

Keywords:

diabetes, drugs, treatment

Abstract

EGHNA, has high prevalence and is strongly related to obesity and diabetes, with great impact at the health level since it is one of the largest causes of end-stage liver disease and transplantation.

There are no specific drugs approved for its treatment, only lifestyle changes show benefits: food plan, based on the Mediterranean diet (high in olive oil, fruits, vegetables, legumes, nuts and fish) weight reduction (5-10%) and exercises (aerobic 3 times a week or resistance 2 times a week).

Author Biography

Karina Fuentes, Private Hospital of Córdoba, Córdoba, Argentina

Physician, Diabetology and Nutrition Service of the Private Hospital of Córdoba

References

-

Downloads

Published

2022-09-01

How to Cite

Fuentes, K. (2022). Symposium 20: Pharmacological treatment of the patient with Non-Alcoholic Fatty Disease (NAFLD). Journal of the Argentine Society of Diabetes, 56(3Sup), 107–107. https://doi.org/10.47196/diab.v56i3Sup.606

Issue

Vol. 56 No. 3Sup (2022): September/December 2022

Section

Symposium Part 4

License

Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.